We Need Your Help! PDF Print E-mail
Tuesday, 09 March 2010 20:51
Today, the Scleroderma Care Foundation embarks upon a mission of vital importance, and we are counting on your help.

One of our dearest Scleroderma patients and friend, Agnes Basil-James, is on the verge of Renal or kidney failure and we are seeking out a qualified kidney donor. Currently, her kidneys are operating at around 2% efficiency and she undergoes dialysis treatment several times per week. Agnes is also the longest known survivor of Scleroderma in Trinidad & Tobago, having been diagnosed with the disease in 1986, some 24 years ago.

As many are aware, Systemic Scleroderma can cause musculoskeletal, pulmonary, gastrointestinal, renal, and other complications. Renal involvement in Scleroderma is typically considered a poor prognostic factor and frequent cause of death. Approximately 5-10% of all Scleroderma patients develop renal crisis at some point in the course of their disease, and is most common in diffuse coetaneous Scleroderma, often associated with antibodies against RNA polymerase (in 59% of cases). Many proceed to dialysis, although this can be stopped within three years in about a third of all cases.

Our programme, for as long as it takes, would seek to find an applicable donor for Agnes. From today, we would be featuring several articles on our site, on the nature and function of the kidneys, and associated renal involvement in Scleroderma. We also seek to provide some assistive and invaluable information on how you can become an organ donor yourself, along with tips for taking much better care of your very own kidneys.

It is our very sincere hope that someone out there, with blood group O, reading this, would be willing to come forward and assist Agnes. We would also like to encourage everyone reading this to please share with family, friends, co-workers, and associates, as our request for assistance may just reach the right person.

Agnes has been so kind as to share with us all, her story, which you can read here. For more information, please do feel free to contact us via email here, or phone at 756-3930 or 685-3213. Also, join us on Facebook or Twitter, where we would post updates as we progress.

Thank you.

Adelwyn Holder
President, Scleroderma Care Foundation
 
More articles :

» Survival In Pulmonary Hypertension

Stephen C. Mathai, Laura K. Hummers, Hunter C. Champion, Fredrick M. Wigley, Ari Zaiman, Paul M. Hassoun, and Reda E. GirgisARTHRITIS & RHEUMATISMVol. 60, No. 2, February 2009, pp 569–577 DOI 10.1002/art.24267 © 2009, American College of...

» What's Your Scleroderma Action Plan?

Living with any serious disease or condition like Scleroderma, is without a doubt, difficult. It is not hard to understand either, that we often can lose sight of what is important, including our way. We may also fall into to a false sense of...

» Targeting Systemic Sclerosis: From Bioinformatics to Clinical Research

Systemic sclerosis (SSc), also known as Scleroderma, is a rare autoimmune connective tissue disorder that's difficult to treat. However, thanks to new research at Dartmouth's Geisel School of Medicine and Northwestern University's Feinberg School of...

» Role of ACE Inhibitors in Preventing Scleroderma Renal Crisis Remains Unclear

Scleroderma patients on angiotensin-converting enzyme inhibitors at the onset of Scleroderma renal crisis do not appear to have worse outcomes than do those not taking the antihypertensive agents prior to the acute renal function deterioration,...

» Testing New Drugs for Early Diffuse Systemic Sclerosis

For patients with the connective tissue disease known as Systemic Sclerosis or – there are few reliable drug treatments. There has been emerging interest in the potential of a class of drugs called (TKI) to ameliorate a major feature of the...

» Rare Disease Research Teams Receive Over $17m In Funding

(CIHR) has formed 9 new research teams that will focus on rare diseases. Funding from the CIHR will total $15.4 million over five years, primarily through the Institute of Genetics and the Institute of Nutrition, Metabolism, and Diabetes, while...